ABSTRACT: Anterior cruciate ligament (ACL) injuries are common and lead to posttraumatic osteoarthritis (PTOA) in a high percentage of patients. Research has been ineffective in identifying successful treatment options for people suffering from symptomatic PTOA resulting in a shift of focus toward the young, ACL injured patients at risk of developing PTOA. Randomized clinical trials examining the very early phase after ACL injury are ideal to study this population; however, these trials face significant challenges regarding recruitment as well as reproducibility of patient-reported outcomes (PROs) and inflammatory and/or chondrodegenerative biomarkers associated with early PTOA. The aim of this work was to develop an approach to allow for early recruitment into an RCT for early treatment following ACL injury and to analyze the variability of commonly used measures and biomarkers at various time points after injury. This paper reports the study design and data related to the first month of treatment for the placebo group of an ongoing 2-year clinical trial to evaluate the effect of an early intra-articular intervention after ACL injury. The results of this study suggest that acute ACL injury results in early changes of both inflammatory and chondrodegenerative biomarkers. These results also provide vital information for researchers to consider when developing future protocols, both related to the logistics of early patient enrollment as well as the appropriate timing of biomarker and patient-reported outcome collection. ß
Posttraumatic Osteoarthritis (PTOA) is a common occurrence in young patients, usually at the beginning or in the middle of their productive work-life. [1] [2] [3] [4] [5] [6] Osteoarthritis (OA) in people under the age of 50 is estimated to cost society $200 billion annually. 1 While the development of treatment approaches for established OA has been studied for many years, the results have ranged from being somewhat encouraging to disappointing. Numerous failed clinical trials would now suggest that late drug intervention, once tissue damage is fully established, will allow for symptom but not disease modification. 7, 8 As a consequence, the research focus has shifted to early detection and early treatment of OA.
In the last decade, it has become apparent that patients who suffer anterior cruciate ligament (ACL) injuries have a very high risk of progression to radiographic and clinically symptomatic OA within 2-5 years after ACL injury. 9, 10 The rupture of the ACL is a dramatic event that usually does not go unnoticed and, in the United States, almost always leads to a surgical reconstruction of the ACL. The prevalence of ACL injury in the United States is high and gradually increased by 36% from 1994 to 2006, with the current estimate for the number of ACL reconstructions performed in the United States of 45/100,000 capita. 11 Up to 50% of young female athletes who suffered an ACL tear have pain with activities of daily living after 10 years and over 85% have radiographic OA. 12 Many of these injuries will lead to the early onset of PTOA, with early detection being difficult as radiographs are generally not sensitive enough to detect the early changes that go along with the development of PTOA. In recent years, however, serum and synovial fluid analysis has been able to describe dramatic inflammatory reactions in knees with early PTOA. [13] [14] [15] [16] Unfortunately, most of these reports have been obtained from sporadic, uncontrolled cohorts of patients with randomly timed synovial fluid and serum samples. However, in order to capitalize on the unique feature of PTOA, a standardized prospective and well-controlled cohort of ACL patients is needed to describe a baseline of intra-articular cytokine and enzymatic changes.
Consequently, we designed a randomized clinical trial (RCT) to address this need and test an early intervention for early inflammatory and chondrodegenerative changes immediately after ACL injury. Enrollment for this trial was based upon the same criteria as the Multicenter Orthopaedic Outcome Network (MOON) cohort. 17 MOON is a nationwide consortium of university centers that began enrollment of a strictly defined ACL injury population into a prospective cohort in 2002. Since then, more than 3,500 patients have been enrolled and longitudinally assessed using subjective patient-reported outcomes (PROs) and objective clinical measures in an effort to better understand the prognosis for ACL reconstruction.
Specifically, we are reporting our early experience and challenges to patient recruitment for this type of trial. Additionally, we report baseline PROs during the first 4 weeks after ACL injury as well as the longitudinal synovial fluid biomarker levels during this time frame. The results of this study provide vital information for development of future research protocols including: Insights related to the logistics of early patient enrollment, data to support a priori power analyses, and recommendations on timing of biomarker and patient-reported outcome collection.
METHODS
We set out to design a multicenter randomized controlled trial evaluating the effect of early anti-inflammatory treatment on the inflammatory and chondrodegenerative changes after acute ACL injury (level of evidence: Level 1 Therapeutic Study Design). 18 To do so, extensive pre-study analysis was necessary to ensure that patients could be identified and enrolled within the first week following injury. This included identification of clinical sites with experience in this area as well as reducing barriers to early enrollment, evaluation, and treatment.
RCT Protocol Design
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A randomized, placebo-controlled, triple-blinded, interventional clinical trial was designed to evaluate the effectiveness of early corticosteroid treatment administered within the first week after ACL injury. However, while the ongoing study was performed to evaluate the effect of this early intervention, the scope of the current study was specific to the study design and implementation. As such, only the control group will be discussed.
Prior to the launch of the study, multiple investigator meetings were held during which the protocol, inclusion and exclusion criteria, procedures, and data capture was carefully discussed. Two formal training sessions conducted by the through the PI and an independent Clinical Study Monitor were held with all involved study personnel. An external Data Safety Monitoring Board, consisting of a biostatistician, an internist, an administrator, a patient representative, and an advising orthopedic surgeon was assembled prior to study initiation. The trial was registered in Clinicaltrials.gov (NCT01692756).
All patients who were referred to participating centers (University Kentucky and Vanderbilt University) with an acute knee injury were assessed for eligibility. After clinical confirmation of an isolated ACL injury (þLachman test with intra-articular effusion, normal varus-valgus test) patients were screened for enrollment in the study. Eligibility criteria are outlined in Table 1 . In brief, patients were included if they were between the ages of 14 and 32, had an isolated ACL injury (no more than a grade 1 MCL injury defined clinically), no history of previous ACL injury (ipsilateral or contralateral knee), injury that occurred during performance of a sporting activity, and growth plates that were closed as documented by plain x-ray.
Patients were excluded if they had a history of any inflammatory disease (e.g., rheumatoid arthritis), immune compromise (due to a disease or a therapeutic intervention), chronic use of NSAIDs, history of intra-articular cortisone injection into either knee within the prior 3 months, known allergy to triamcinolone acetonide, prior knee surgery, or had participated in another clinical drug trial within the prior 4 weeks. Prior to enrollment, all patients were consented and/or assented according to the University of Kentucky and Vanderbilt University Internal Review Boards (IRB) approved consent/assent forms. All patients underwent knee aspiration to dryness at initial encounter (within 8 days after ACL injury), 6-10 days after the initial encounter, and at the time of surgery (Fig. 1) . Patients in the placebo group received two consecutive intra-articular saline placebo injections at the same time periods.
Data Capture Methods
Once a patient was identified, group allocation was performed by permutated block randomization. An independent statistician created the randomization scheme in equal eight patient block sizes. No stratification was performed in the design of the block randomization scheme. This design was chosen to allow for the potential transfer of randomization blocks should there be enrollment problems at one of the centers. Subject numbers were assigned to 34 boxes at each center. Each box contained the supplies necessary for the blood and synovial fluid draws as well as the labels and randomization sheet indicating the group and instructions for drawing up the injection. An unblinded athletic trainer or pharmacist, not directly involved with the study, drew up the study medication according to the randomization sheet and handed the investigator an opaque syringe with the appropriate study drug.
Joint aspiration was performed aseptically with local anesthesia via a superolateral suprapatellar approach. The aspiration syringe was gently removed and the study drug/ placebo-containing syringe was attached, followed by injection. Intraarticular placement was confirmed using the "squish" test as described by Glattes et al. 19 Synovial fluid was spun at 3500 RPM for 10 min and the supernatant was frozen at À80˚C. Serum samples were obtained through antecubital fossa venipuncture and spun at 3,500 RPM to separate the serum. Serum was then aspirated into a separate tube and frozen at À80˚C. Urine samples were collected, spun, and frozen in a similar fashion. The samples were initially stored on site at À80˚C in a freezer, and subsequently aliquoted according to an allotment protocol. Once all site samples were collected they were shipped to the Duke University biomarker laboratory (VBK/JLH) for analysis. 18 Multiple synovial fluid biomarkers were analyzed according to Osteoarthritis Research Society International (OARSI) guidelines. 20 The category and list of biomarkers chosen for analyses at each of the three study time points included the following: Synovial inflammation-interleukin-1-a (IL-1a), interleukin-1-b (IL-1b) (Meso Scale Discovery, Rockville, MD), and interleukin-1-receptor antagonist (IL-1ra) (R&D Systems, Minneapolis, MN); cartilage degeneration-cartilage oligomeric matrix protein (COMP) (BioVendor, Asheville, NC), collagen type II breakdown (Cartilaps 1 (CTX-II) (Immunodiagnostic Systems, Inc, Fountain Hills, AZ), sulfated glycosaminoglycan (sGAG) (Kamiya Biomedical Company, Seattle, WA), matrix metalloproteinases (MMP-1, MMP-3, and MMP-9) (Meso Scale Discovery, Rockville, MD), collagen type I breakdown (Osteomark 1 NTx; Alere, Scarborough, ME); and an inflammation-induced repair response-the hyaluronan stabilizing protein tumor necrosis factorstimulated gene 6 protein (TSG-6). 21 Greater concentrations of the aforementioned biomarkers are associated with increased inflammation or cartilage degradation with the exception of COMP in which lesser values are associated with increased degradation. 22 Patient-reported outcomes were also collected at the time of enrollment (Time 1) and day of surgery (Time 3). Patients completed the Knee Injury and Osteoarthritis Outcome Scale (KOOS), International Knee Documentation Committee Subjective Knee Form (IKDC), and the Pain Catastrophizing Scale (PCS). [23] [24] [25] The standardized patient self-report KOOS instrument was used to assess pain and function in response to the intervention for acute ACL injury. 24 The KOOS consists of five subscales (pain, other symptoms, function in daily living, function in sport and recreation, and kneerelated quality of life). We opted not to include the sport and recreation subscale in the current analysis as scores immediately following ACL injury may be influenced by both the timing of injury as well as the current standard of postinjury care. Surgeons often instruct patients to limit sporting and dynamic activities following ACL injury and, as such, the sport and recreation score may be more indicative of the instructions given to the patient than the patient's selfperceived ability to perform these tasks. Finally, we supplemented the four KOOS subscales with global score of knee pain and function from the IKDC form for evaluation of knee ligament injuries. 25 Pain coping strategies are important in understanding improvements in pain and psychological disability. [26] [27] [28] We used the Pain Catastrophizing Scale as a pain assessment tool, with scores ranging from 0 to a maximum possible score of 52 (larger values being indicative of more pronounced catastrophizing behavior). Pain catastrophizing has been identified as one of the strongest predictors of pain and has been defined as "an individual's tendency to focus on and exaggerate the threat value of painful stimuli and negatively evaluate one's own ability to deal with pain." 29 Not only do individuals who catastrophize experience more experimental pain, [29] [30] [31] [32] but catastrophizing has also been shown to account for 7-31% of the variance in pain ratings in varied populations of patients having persistent pain. It has been associated with heightened anxiety, depression, increased pain behaviors, increased use of health care services, and analgesic medication. Thus, "catastrophizing has risen to the status of one of the most important psychological predictors of the pain experience." 29 In a study of patients undergoing ACL surgery, Pavlin et al. found that high pain catastrophizers were much more likely to report high levels of post-operative pain, had longer durations of moderate to severe pain, and were less likely to report adequate pain control at home. 30 Site Selection Two sites participated in this collaborative effort. The University of Kentucky (Lexington, KY) and Vanderbilt University (Nashville, TN) were selected based on available patient volume and experience with Multicenter Orthopaedic Outcome Network (MOON) patient enrollment. The University of Kentucky and Vanderbilt University have strong patient referral bases allowing for enrollment following ACL injury (within eight days). Both universities have extensive primary care and physician extender networks capable of identifying and referring patients suspected of ACL injury directly from the playing fields to the orthopaedic clinics. Vanderbilt University as the coordinating center of the MOON cohort study has shown historically that patients with the MOON inclusion criteria can be successfully recruited. 33, 34 At the University of Kentucky, a retrospective analysis of all ACL reconstructions (ACLR) in the 4 years prior to study implementation (2009-2013) was conducted. This analysis yielded a total of 1493 ACLR with an average of 373 ACLR per year. Over half of ACLR (n ¼ 864, 58%) were classified as "acute" (less than 30 days from injury). More than 70% (n ¼ 1080) of patients were between the ages of 15 and 34 years of age. This pre-study analysis indicated that the University of Kentucky historically treats a large number of ACL injuries within an "acute window" in the relevant age group.
Statistical Analyses to Assist Future Protocol Development
An additional pre-study analysis was performed to identify the barriers to patient enrollment that might prevent ACUTE ACL INJURY AS A MODEL FOR EARLY POSTTRAUMATIC ARTHRITIS evaluation within the 8-day window after ACL injury selected for this protocol. At the University of Kentucky, a formal enrollment study was performed. Over the course of 4 months (January-May, 2011), a total of 65 patients with ACL injuries were treated. Twenty-nine study-eligible patients were identified of which 23 were seen by a surgeon within 30 days post injury. Only 13 patients (45%) saw a surgeon in the first 8 days, but 25 (86%) saw a primary care physician or surgeon in our institution in the first week. Ten (34%) of those patients were seen in the first 3 days after injury. This analysis prompted us to change the protocol to include primary care physicians at the University of Kentucky. In addition to this protocol modification, an athletic trainer was placed in every primary care and orthopaedic clinic to facilitate enrollment of study-eligible patients. While these changes were implemented at the University of Kentucky, no additional changes were necessary at Vanderbilt University due to their previous experience in the enrollment of an onsite cohort within the MOON-longitudinal cohort study that enrolled 120 patients with the designated inclusion criteria utilized for this protocol over the course of 2 years.
The effect of implementing referral pattern changes at the University of Kentucky on the ability to enroll patients in the time window of the proposed study were evaluated by performing a Fisher Exact test. This was performed by comparing the number of patients seen during the first 8 days after injury prior to and following the implementation of the aforementioned referral pattern changes. To better understand both the inherent variability of both biomarkers and patient-reported outcomes following acute ACL injury, we evaluated the change in all dependent variables between initial enrollment and the time of ACL reconstruction. We limited these analyses to patients randomized to the placebo group from a single site (n ¼ 10). A report on the full placebo and treatment data are in preparation. Repeated measures ANOVAs with Bonferroni post hoc analyses were used to identify the potential timing of changes in all biomarkers at the three preoperative time points. Paired t-tests were used to determine if patient-reported outcomes differed between initial enrollment and the time of ACL reconstruction. In addition, Cohen's d effect sizes were calculated to determine the magnitude of change for all biomarkers and patientreported outcomes between initial enrollment and the day of surgery. 35 An a-level of p < 0.05 was considered statistically significant and all analyses were performed using SPSS Statistics 23 (IBM, Armonk, NJ).
RESULTS
Over the course of the study period, 224 primary ACL reconstructions were performed at the University of Kentucky. Of these, 86 patients were screened for eligibility shortly after ACL injury with 41 patients that met the inclusion and exclusion criteria electing to participate. Of the 45 that were not enrolled, 41 did not meet the inclusion and exclusion criteria and four patients chose not to participate. The implementation of the referral pattern changes at the University of Kentucky significantly improved the patient access during the first 8 days after injury with 41/41 (100%) of the patients that were enrolled being seen compared to 13/29 (45%) during our pre-study analysis (p ¼ 0.0001).
Ten patients randomized to the placebo group were included in this report of the longitudinal analyses of biomarkers and PROs following acute ACL injury (six females, four males; age 17.9 AE 2.2 years; BMI 22.1 AE 1.9 kg/m 2 ). The mean (range) time between Table 2 ).
In contrast, biomarker results were much more variable (Table 3) . While some markers such as COMP and CTX-II steadily changed over the 4 weeks between ACL injury and surgery (Figs. 3 and 4) , other markers did not statistically change over this time period (IL-1a, IL-1b, MMP-3, MMP-9, NTx, and TSG; Table 3 ). sGAG did not change between Times 1 and 2 but significantly decreased at Time 3 (Fig. 5) . MMP-1 also demonstrated a different response pattern than other markers, increasing at Time 2 but then significantly decreasing at Time 3 (Fig. 6 ). Of particular note was the variability in the initial IL-1ra measures. Despite values 10-fold higher than what was observed at Times 2 and 3, the Time 1 values did not statistically differ from these other time points largely due to the inter-subject variability (Fig. 7) .
DISCUSSION
Both COMP and CTX-II demonstrated changes over the first 4 weeks after ACL injury suggesting that the chondrodegenerative process begins immediately after injury. This small feasibility trial is of importance to those interested in early interventions to potentially modify the inflammatory and/or chondrodegenerative response immediately following ACL injury. The current results suggest that studies employing early interventions within a few days after ACL injury are feasible, even in multicenter designs.
This study provides helpful information related to specific patient inclusion/exclusion criteria and methods to reduce barriers to early patient enrollment and data collection. We defined a very specific patient group based upon the MOON enrollment criteria. In addition, we limited eligibility based upon the time point from injury to include only patients who were enrolled within 8 days after injury. While our initial practice approach did not allow for a potentially successful enrollment, we were able to implement practical changes of our referral structure by including primary care physicians and physician extenders into the recruitment process for this study. This change allowed us to successfully enroll 41 patients over 15 months even though only 18% of all patients presenting with ACL injuries during this time frame met inclusion criteria for enrollment into the trial. Another key finding is that 71% of all enrolled patients were under the age of 21. This fact becomes particularly important with respect to the identification of future early treatment options as 71% of the enrollees fall under the FDA definition of "minors or children." All of our patients had closed growth plates as documented via knee radiographic examination and are being treated identically to adult patients with ACL injuries. With regards to the development of early interventional therapies, this may have to be addressed by federal regulators as the use of many potential agents is restricted to adults.
The current results also highlight key information to be used when developing future protocols. First, our results provide other researchers with data necessary to perform a priori analyses to assist in the justification of sample sizes necessary for future trials. Second, to our knowledge these are the first results demonstrating the longitudinal changes in both biomarkers and patient-reported outcomes immediately following acute ACL injury.
The biomarkers assessed in the current study demonstrated variable patterns of response following (Fig. 7) . Nevertheless, results were consistent for the five synovial fluid biomarkers we measured which also agrees with a previous that study evaluated biomarker concentrations during the initial month after ACL injury. CTX-II significantly and steadily increased, COMP and sGAG significantly and steadily declined, and MMP-3 remained elevated throughout the sampled timepoints. 22 Taken together, Figure 5 . sGAG (mg/ml) significantly decreased from Times 2 to 3. Figure 6 . MMP-1 (pg/ml) increased by Time 2 but then significantly decreased between Times 2 and 3.
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these results reflect a slowing of degradation of the non-collagenous matrix after injury but a steadily increasing degradation of type II collagen possibly marking an irreversible process. These findings are consistent, as noted in the prior study, 22 with the temporal patterns of matrix epitope release in vitro from cartilage explants stimulated with proinflammatory cytokines in which there is an initial loss of proteoglycan followed by collagen loss. While this information can assist researchers to determine the most appropriate time point(s) to collect for a particular biomarker of interest, it is our opinion that the different response patterns and large inter-subject variability highlight the need for longitudinal data collection with multiple data collection time points.
Unlike biomarkers, patient-reported outcomes demonstrated a clear pattern of recovery over the first 4 weeks after injury in the placebo group (two serial arthrocentesis and saline injection) (Fig. 2) . This is not unexpected, as the response to two joint aspirations that can reduce proinflammatory intraarticular blood components and relieve high intraarticular pressure may themselves be beneficial. Given that all outcome tools used in this trial improved during this period, we suggest that future studies should standardize the timing of preoperative administration of patient-reported outcome questionnaires. If evaluating a preoperative intervention, our results suggest that patient-reported outcomes should be administered as soon after injury as possible, and also highlight the need for a control group consisting of a double-blinded placebo group as large effect sizes were observed for all patientreported outcomes that were evaluated. This small feasibility study was not without limitations. First, this exploratory study was likely underpowered to statistically identify time-related changes due to the variability of certain biomarkers. For example, time-dependent effects were not identified with either IL-1a and IL-1b despite large effect sizes. As previously mentioned, this is likely due to large inter-subject variability; however, this variability can be counterbalanced with larger sample sizes. Second, we evaluated a placebo group; however, a "true" control group (i.e., intra-articular needle insertion without fluid withdrawal) was not feasible. The placebo group was aspirated on three occasions prior to surgery whereas commonly the standard of care does not involve routine preoperative aspiration. It remains unclear if aspirating the milieu of inflammatory cells and fluid within the first 4 weeks after ACL injury may have a beneficial effect.
In conclusion, we have established that acute ACL injury results in longitudinal changes of both inflammatory and chondrodegenerative biomarkers. The results of this study also provide vital information for researchers to consider when developing future protocols, both related to the logistics of early patient enrollment as well as the appropriate timing of biomarker and patient-reported outcome collection.
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